LifeVantage Corporation Q2 2026 Earnings Recap

LFVN Q2 2026 February 5, 2026

Get alerts when LFVN reports next quarter

LifeVantage reported a notable decline in revenue this quarter due to increased competition in the GLP-1 market, despite progress in product diversification and integration from the LoveBiome acquisition.

Earnings Per Share Miss

$0.15 vs $0.19 est.

-21.1% surprise

Revenue Miss

48931000 vs 54402330 est.

-10.1% surprise

Market Reaction

1-Day -16.76%

5-Day -11.17%

30-Day -16.22%

See LFVN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q2 revenue decreased significantly as competition from pharmaceutical GLP-1 drugs intensified, impacting sales of the MINDBODY GLP-1 system.
Successful launch of two new products from the LoveBiome acquisition, aimed at enhancing consumer engagement and expanding the product portfolio.
Continued development of the patent-pending P84 product, which shows promise in the gut health sector and is gaining traction among consumers.
Progress on the Shopify partnership is set to modernize e-commerce capabilities, enhancing customer experience and conversion rates.
Strategic focus on international market expansion positions the company for growth despite current challenges in the GLP-1 segment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LFVN on AllInvestView.

Next Q3 2026